CENTRIENT PHARMACEUTICALS LLC

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2020–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	3	1
2025	—	4	1
2024	—	4	1
2023	—	4	1
2022	—	5	1
2021	—	4	1
2020	—	4	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
AKIN GUMP STRAUSS HAUER FELD	—	28

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
SENATE	22
Health & Human Services, Dept of (HHS)	21
HOUSE OF REPRESENTATIVES	20
Natl Economic Council (NEC)	18
Natl Security Council (NSC)	12
Commerce, Dept of (DOC)	8
Food & Drug Administration (FDA)	6
Office of Management & Budget (OMB)	5
White House Office	5
Office of Science & Technology Policy (OSTP)	3
State, Dept of (DOS)	3
U.S. Trade Representative (USTR)	3
Overseas Private Investment Corp (OPIC)	2
Natl Security Agency (NSA)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Pharmacy	Pharmacy	26
Health Issues	Health Issues	26
Manufacturing	Manufacturing	25
Defense	Defense	7
Budget/Appropriations	Budget/Appropriations	3
Trade (domestic/foreign)	Trade (domestic/foreign)	2

Bills Explicitly Cited (4)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 8070118th Congress

Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025

2024 · fourth_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to health care supply chain and domestic pharmaceutical manufacturing; H.R.8070 - Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025; S.4638 - National Defense Authorization Act for Fiscal Year 2025.

Client expense: — · Firm income: $10,000

Matched citations: H.R.8070

S. 4638118th Congress

National Defense Authorization Act for Fiscal Year 2025

2024 · fourth_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to health care supply chain and domestic pharmaceutical manufacturing; H.R.8070 - Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025; S.4638 - National Defense Authorization Act for Fiscal Year 2025.

Client expense: — · Firm income: $10,000

Matched citations: S.4638

H.R. 8070118th Congress

Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025

2024 · third_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to health care supply chain and domestic pharmaceutical manufacturing; H.R.8070 - Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025; S.4638 - National Defense Authorization Act for Fiscal Year 2025.

Client expense: — · Firm income: $30,000

Matched citations: H.R.8070

S. 4638118th Congress

National Defense Authorization Act for Fiscal Year 2025

2024 · third_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to health care supply chain and domestic pharmaceutical manufacturing; H.R.8070 - Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025; S.4638 - National Defense Authorization Act for Fiscal Year 2025.

Client expense: — · Firm income: $30,000

Matched citations: S.4638

Source: Senate LDA

CENTRIENT PHARMACEUTICALS LLC — Lobbying Disclosure | Poliscope